




Turnover grows 8% to 789 million euro

Nazareth, Belgium 17 January 2008 – The consolidated turnover in 2007 totalled 789.1 million euro. This is 8% higher than the previous year. Internal growth was 2% on an annual basis.

The evolution of the turnover per business units is as follows:

<i>Non-audited management figures</i>	Fourth Quarter			Full Year		
in EUR million	2007	2006	Evolution	2007	2006	Evolution
Omega Pharma Belgium	46.0	60.4	-24%	198.7	220.2	-10%
Omega Pharma France	52.1	50.2	+4%	190.4	172.8	+10%
Omega Pharma Other Territories	102.7	82.9	+24%	400.0	336.4	+19%
<i>Omega Pharma North-Europe</i>	21.2	21.0	+1%	99.6	96.3	+3%
<i>Omega Pharma South-Europe</i>	33.6	29.1	+16%	143.1	129.6	+10%
<i>Omega Pharma Rest Of World</i>	47.9	32.8	+46%	157.2	110.5	+42%
Omega Pharma (OTC)	200.8	193.5	+4%	789.1	729.4	+8%

Contribution to the consolidated annual turnover of the group in 2007



With 789.1 million euro, Omega Pharma has achieved an annual turnover which is situated in the middle of the prognosis communicated on 18 October 2007. The strongest performances were delivered by Omega Pharma France and by the organizations in Southern Europe and in Central and Eastern Europe. The turnover generated beyond the Belgian home market has grown by 16% – with a solid internal growth of 6%.

All Core Categories witnessed a *double digit* or *high single digit* growth in turnover. The turnover of Natural Remedies & Slimming – including brands like XLS, Davitamon, Silence, and Aflubin – showed the strongest growth (+82%, or +12% excluding external growth).

Considering the strengthened balance sheet following the carve-out of Arseus, the Board of Directors took the decision in mid-November that a share buy-back represented the optimal way to appropriate the free cash flow for creating shareholder value. Today, Omega Pharma holds 1,434,994 treasury shares or 5.48% of the total number of outstanding shares. The total mandate runs until the shareholders meeting of 5 May 2008 and enables the company to hold up to 2,522,794 treasury shares or 9.63% of all outstanding shares.

Strong growth in France, South Europe, Central, and East Europe; a temporary slowing in Belgium

In 2007, **Omega Pharma Belgium** clearly felt the effects of external factors in the business environment, leading to negative growth. The abnormal weather patterns in the summer severely depressed the 3rd quarter sale of seasonal product families in Belgium. In addition, the dynamics in the sale of generic medicines witnessed a significant slow-down in Belgium, both in the 3rd and the 4th quarter. In order to be able to better anticipate these changes in the business environment, a management replacement has been implemented early January.

Following six consecutive quarters of sales growth at **Omega Pharma France**, it can be concluded that the turnaround is fully successful. Even excluding the turnover of Persee Médica, that was acquired in 2007, the French organization scores a 4% growth on an annual basis. This figure is substantially better than the total market growth in France.

Within the **Northern Europe** region, the Scandinavian organizations have scored a solid growth in turnover. This strong performance has been partially offset by the weak development of sales in Germany, thus resulting in a 3% overall growth for Northern Europe. With the recent replacement of management with the previous Norway Country Manager, the business model for dermocosmetics which is so successfully applied in Scandinavia is now also being implemented at the German organization. Consequently, Omega Pharma can also face the future in this country with confidence.

The organization in **Southern Europe** posted a solid growth in 2007. With an annual turnover of 143 million euro and a pure organic growth of 10%, this entity has met all expectations.

In the **Rest of World** segment, growth in turnover is 42%. This increase is mainly due to the turnover in Central and Eastern Europe, where Omega Pharma has gained a direct presence only since January 2007. This presence is a consequence of the acquisition of Bittner Pharma. In the Emerging Markets, Omega Pharma achieved an annual turnover of 69.4 million euro versus 16.5 million euro in 2006. The group is ready to roll out the first three Star Brands into this region in the course of 2008, and to develop further synergies.

Prognosis ⁽²⁾

Omega Pharma confirms its ambition to achieve over 1 billion euro turnover by 2010. For 2008, Omega Pharma anticipates an internal growth between 3% and 7%, depending in part upon legislation affecting generic medicines in Belgium.

Omega Pharma, a pure OTC play

Since its creation in 1987, Omega Pharma has grown into a multinational group with almost 2,000 staff and with operations in 30 countries spread over Western, Central, and Eastern Europe. Omega Pharma is one of the few companies dealing solely in OTC products. With its current geographical spread, the group is poised to enter the worldwide Top Ten ranking in the market for over-the-counter medicines and personal care products. The group has the ambition of becoming a world player in OTC by continuing the development of activities beyond Western Europe. A major step was taken in that direction in 2007, as shown by the fact that the strongest growth in 2007 was achieved in the Emerging Markets.

Notes

- (1) In conformity with the International Financial Reporting Standards (IFRS) the profit and loss statement 2007 will only show the annual turnover of the Consumer Health activities – i.e. no turnover of Arseus will be mentioned. Underneath the line with the result of the period for the Consumer Health activities, the results of Arseus (100% for the first nine months of 2007; 24% for the remaining three months) will be added to the consolidated group results.
- (2) Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be

Tel. 0032/9/381.03.31 - Mobile 0032/499/58.55.31